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Abstract
Harboyan syndrome is a degenerative corneal disorder defined as congenital hereditary endothelial
dystrophy (CHED) accompanied by progressive, postlingual sensorineural hearing loss. To date, 24
cases from 11 families of various origin (Asian Indian, South American Indian, Sephardi Jewish,
Brazilian Portuguese, Dutch, Gypsy, Moroccan, Dominican) have been reported. More than 50% of
the reported cases have been associated with parental consanguinity. The ocular manifestations in
Harboyan syndrome include diffuse bilateral corneal edema occurring with severe corneal clouding,
blurred vision, visual loss and nystagmus. They are apparent at birth or within the neonatal period
and are indistinguishable from those characteristic of the autosomal recessive CHED (CHED2).
Hearing deficit in Harboyan is slowly progressive and typically found in patients 10–25 years old.
There are no reported cases with prelinglual deafness, however, a significant hearing loss in children
as young as 4 years old has been detected by audiometry, suggesting that hearing may be affected
earlier, even at birth. Harboyan syndrome is caused by mutations in the SLC4A11 gene located at
the CHED2 locus on chromosome 20p13-p12, indicating that CHED2 and Harboyan syndrome are
allelic disorders. A total of 62 different SLC4A11 mutations have been reported in 98 families (92
CHED2 and 6 Harboyan). All reported cases have been consistent with autosomal recessive
transmission. Diagnosis is based on clinical criteria, detailed ophthalmological assessment and
audiometry. A molecular confirmation of the clinical diagnosis is feasible. A variety of genetic,
metabolic, developmental and acquired diseases presenting with clouding of the cornea should be
considered in the differential diagnosis (Peters anomaly, sclerocornea, limbal dermoids, congenital
glaucoma). Audiometry must be performed to differentiate Harboyan syndrome from CHED2.
Autosomal recessive types of CHED (CHED2 and Harboyan syndrome) should carefully be
distinguished from the less severe autosomal dominant type CHED1. The ocular abnormalities in
patients with Harboyan syndrome may be treated with topical hyperosmolar solutions. However,
corneal transplantation (penetrating keratoplasty) represents definitive treatment. Corneal
transplantation produces a substantial visual gain and has a relatively good surgical prognosis.
Audiometric monitoring should be offered to all patients with CHED2. Hearing aids may be
necessary in adolescence.
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Corneal dystrophy and perceptive deafness (CDPD,
OMIM 217400), Corneal dystrophy with progressive sen-
sorineural deafness, Corneal dystrophy and sensorineural
prelingual deafness, Harboyan syndrome.
Background
The non syndromic endothelial (posterior) corneal 
dystrophies
The anterior segment of the vertebrate eye is highly spe-
cialized and comprises the cornea, trabecular meshwork,
iris and lens, whose co-development is essential to normal
vision. Amongst these the cornea is the major refracting
structure consisting of an anterior stratified epithelium, a
paucicellular stroma and an endothelium covering its
posterior aspect. The endothelium is a monolayer of
polygonal cells that is pivotal to anterior segment devel-
opment and that maintains corneal transparency by keep-
ing the stroma in a state of relative dehydration [1].
A number of inherited disorders of the cornea have been
described in humans [2]. The endothelial (posterior) cor-
neal dystrophies (see Table 1[3-9]), which result from pri-
mary endothelial dysfunction, include Fuchs endothelial
dystrophy (FECD1 – MIM136800; FECD2 –
MIM610158), posterior polymorphous dystrophy
(PPCD1 – MIM122000; PPCD2 – MIM609140; PPCD3 –
MIM609141) and congenital hereditary endothelial dys-
trophy (CHED: CHED1 – MIM121700 and CHED2 –
MIM217700). They all are thought to represent defects of
terminal differentiation of neural crest [10]. This group
shares many features including corneal decompensation,
altered morphology of endothelial cells, and secretion of
an abnormal collagenous layer in the posterior zone of
Descemet's membrane (DM), the endothelial basement
membrane [11,12].
FECD is the commonest primary disorder of the corneal
endothelium. Signs may be present from the fourth dec-
ade of life onwards with the development of focal wart-
like guttata in the central cornea arising from Descemet's
membrane. The latter is thickened with abnormal colla-
genous deposition. There is reduced endothelial function
and cell density as well as cellular pleomorphism. FECD is
usually a sporadic condition but familial, highly pene-
trant forms showing autosomal dominant inheritance are
also recognized [13].
PPCD is a rare bilateral corneal endothelial dystrophy that
is inherited in an autosomal dominant manner. The clin-
ical features usually present earlier than FECD, and may
be present at birth. The condition is characterized by the
formation of blister-like lesions within the corneal
endothelium or by regions of endothelial basement mem-
brane thickening with associated corneal oedema. Epithe-
lial-like cells are found in place of the normal amitotic
endothelial cells [14], showing abundant intermediate fil-
aments, desmosomes and microvilli [15]. The endothe-
lium becomes multilayered and the abnormally
proliferating cells may extend outwards from the cornea
over the trabecular meshwork and cause glaucoma.
CHED is believed to result from the hypoplasia or degen-
eration and dysfunction of the endothelial cells [16]. It
can be inherited in an autosomal dominant (CHED1) and
an autosomal recessive (CHED2) manner. The endothe-
lium regulates corneal hydration by actively pumping out
water from the stroma into the aqueous humor. The Na/K
ATPase-driven ion pump plays a crucial role in this mech-
anism [1]. Excessive water entry into the stroma causes
disruption of the collagen fibrils resulting in scattering of
light and opacification. Histological features of CHED-
affected corneas include diffuse epithelial and stromal
edema, defects in the Bowman membrane, paucity of
endothelial cells showing degenerative changes e.g. multi-
nucleated cells, and a thickened Descemet's membrane
reflecting an abnormal secretion by the endothelial cells
[17,18].
The autosomal dominant (CHED1) and recessive
(CHED2) forms are clinically and genetically distinct
[19], and may be distinguished by age at time of onset and
by the presence or absence of accompanying signs and
symptoms. CHED2 presents at birth or within the neona-
tal period, while CHED1 usually develops later in child-
hood. Clinically, CHED2 is generally more severe than
CHED1.
Table 1: The endothelial (posterior) corneal dystrophies – inheritance and onset
CHED1 CHED2 PPCD1 PPCD2 PPCD3 FECD1 FECD2
Inheritance Dominant Recessive Dominant Dominant Dominant Dominant Sporadic or Dominant and more severe in 
females
Gene 20p11.2-q11.2 [3] SLC4A11 [4] VSX1 [5] COL8A2 [6] TCF8 [7] COL8A2 [6] 13pTel-13q12.13 and 18q21.2-q21.32 [8,9]
Onset Early Birth Early Early Early Early Late, 4th decadePage 2 of 8
(page number not for citation purposes)
Orphanet Journal of Rare Diseases 2008, 3:28 http://www.ojrd.com/content/3/1/28Harboyan syndrome is an eye and ear disease, consisting
of:
- Congenital hereditary endothelial dystrophy, indistin-
guishable from CHED2.
- Progressive, postlingual sensorineural hearing loss,
mainly affecting the higher frequencies, with first symp-
toms typically reported in the teenage years.
- All reported cases have been consistent with autosomal
recessive inheritance.
Epidemiology
Population-based epidemiological data for Harboyan
syndrome are not available as there are only seven reports
of this syndrome in the literature [20-26]. The eleven fam-
ilies reported (24 cases affected) were from various origin
(Brazilian Portuguese, Netherlands, Gypsy, Moroccan,
Asian Indian, South American Indian, Sephardi Jewish,
Dominican). It is of interest that, while more than half of
the reported cases were associated with parental consan-
guinity, several cases resulted from compound heterozy-
gosity (see below), suggesting that carrier frequency may
not be extremely low.
Harboyan syndrome appears to be rarer than CHED2.
Before the discovery of the gene implicated in the CHED2
etiopathogenesis in 2006, only several cases of CHED2
have been reported. Since then, causative mutations have
been detected in 92 CHED2 families originating mainly
from regions with a high rate of consanguinity (e.g. some
regions of India) [4,20,27-33]. As hearing loss in Har-
boyan syndrome is slowly progressive and may long
remain undetected and, at the same time, monitoring of
hearing has not been reported in CHED2 patients, it is
possible that some cases of Harboyan syndrome are cur-
rently reported as nonsyndromic CHED2.
Clinical description
CHED presents as a ground glass, bluish-white opaque
cornea (Figure 1A). It is due to diffuse edema of the
stroma resulting from endothelial cell dysfunction [16]
and leads to visual loss (the presence of an otherwise nor-
mal anterior segment).
Harboyan syndrome, similarly to CHED2, manifests as a
diffuse, bilateral corneal edema, with a "ground glass cor-
nea" appearance. Corneal clouding is observed at birth or
within the neonatal period, with minimal progression
over time. The most frequent additional sign is nystag-
mus, which is presumably caused by the severe corneal
clouding present from early in life.
Hearing loss in Harboyan syndrome is not reported at
birth, and no case of prelingual deafness has been
reported so far. It is sensorineural, slowly progressive,
with typical deficits in the 20–50 db range (mild to mod-
erate) at ages 10–25 yrs, and mainly affects the higher fre-
quencies (Figure 2). Although symptomatic hearing loss is
not reported in early childhood, it might probably be
detected in the first years of life if sought [24]. In families
with Harboyan syndrome, hearing loss (when investi-




In 1995, Toma performed genetic linkage analysis with
microsatellite markers on a seven generation British
CHED1 pedigree, and mapped CHED1 to a 2.7cM region
of chromosome 20p11.2-q11.2 with a multipont lod
Eye phenotype, untreated adult with Harboyan syndromeFigure 1
Eye phenotype, untreated adult with Harboyan syndrome. The cornea presents congenitally with a ground glass, blu-
ish-white opaque cornea from diffuse edema of the stroma (1A). Slit lamp examination showing milkiness and increased thick-
ness of the corneal (1B).Page 3 of 8
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Sensorineural hearing loss in Harboyan syndromeFigure 2
Sensorineural hearing loss in Harboyan syndrome. Typical hearing loss in three Harboyan patients. Hearing deficit is in 
the 20–50 db range (mild to moderate), mainly affecting the higher frequencies. 2A: Patient 1 at 33 years (right and left ear). 2B: 
Patient 2 at 18 years. 2C: Patient 3 at 19 years.
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cM region lied within the 30 cM region linked to posterior
polymorphous dystrophy (PPD). PPD is genetically heter-
ogeneous, and PPD at 20p11 has been associated with
mutations in the paired-like homeodomain gene VSX1
[5]. The CHED1 gene remains unknown.
In 1999, a large, consanguineous Irish pedigree with
CHED2, was linked to chromosome 20p13 with a maxi-
mum lod score of 9.30 at microsatellite marker D20S482.
The critical region of homozygosity spanned 8 cM
between markers D20S113 and D20S882. Mapping data
clearly indicated that the autosomal recessive CHED2
gene was distinct from the autosomal dominant CHED1
gene [34].
Harboyan syndrome was also mapped to 20p13 in one
large consanguineous Moroccan family between markers
D20S199 and D20S437 with a maximum multipoint lod
of 4.20 at D20S889/D20S179 [26]. The locus was named
CDPD1. The critical 7.73 cM linkage region overlapped
the linkage region of autosomal recessive CHED2.
In 2006, analysis of the SLC4A11 gene located within the
linkage overlap, in CHED2 patients showed seven differ-
ent mutations in ten families. Mutations were predicted to
cause loss of protein function either by impeding mem-
brane targeting or by nonsense-mediated decay [4]. The
study of 3 consanguineous and 3 nonconsanguineous
families with Harboyan syndrome revealed homozygosity
or compound heterozygosity, respectively, for SLC4A11
mutations in Harboyan patients, indicating that CHED2
and Harboyan syndrome are allelic disorders [20]. A total
of 62 different SLC4A11 mutations have been reported in
98 families (92 CHED2 and 6 Harboyan) [4,20,27-33].
Roughly the same proportion of truncating and missense
mutations have been observed in both disorders, with no
obvious clustering of mutations. Of note, two residues
were found mutated in both CHED2 and Harboyan
patients. The first case was deletion 473_480del8bp. The
predicted protein change was however slightly different in
the two reports: Arg158GlnfsX4 in CHED2 [31], and
Arg158ProfsX4 in Harboyan [20], because of a single
nucleotide polymorphism (SNP, rs3827075) at the nucle-
otide immediately following the deletion, which was A/A
in the CHED2 patient and C/C in the Harboyan patient.
In the second case, the same residue, Serine 213, was
involved in two different missense mutations: c.638C→T
(Ser213Leu) in a CHED2 patient [25], and c.637T→C
(Ser213Pro) in a Harboyan patient [20]. The latter Har-
boyan patient was a compound heterozygote, and her sec-
ond mutation (Met856Val) might theoretically explain
the different phenotype. It remains possible that some
cases reported as CHED2 consisted in fact of unrecognised
Harboyan cases in whom hearing loss had not yet devel-
oped, or had been overlooked.
Heterozygous SLC4A11 mutations have recently been
reported in Fuchs endothelial corneal dystrophy (FECD),
a late-onset progressive disorder of the corneal endothe-
lium, indicating that carriers parents of affected CHED2 or
Harboyan children might be at risk of developing late-
onset corneal dystrophy [35]. Association of Fuchs and
either CHED or Harboyan syndrome in the same family
has however not been reported so far.
Pathophysiology
SLC4A11 encodes a ubiquitous electrogenic sodium-cou-
pled borate transporter (also called BTR1 or NABC1)
which is essential for cellular boron homeostasis, and
whose defect hampers cell growth and proliferation [36].
SLC4A11 is related to the SLC4 family of transport pro-
teins, which consists of a functionally diverse group of 11
members that play an essential role in the transport of
HCO3- [37]. Although SLC4A11 is a highly selective
boron concentrating transporter, in boron-free medium,
it functions as a Na+ and OH- permeable channel [36].
CHED2 was the first human disease associated with a
boron transporter defect, although boron homeostasis
remains poorly understood in humans. Consistent with
SLC4A11 mutations as a cause of hearing loss, this gene is
expressed in the cochlea of adult mice, more specifically at
the level of the lateral wall, which contains the stria vascu-
laris [38], the latter being involved in the highly distinc-
tive homeostasis of cochlear fluid and endolymph
secretion. Considering the highly specific constitution of
the endolymph and the expression of the gene in the stria
vascularis [38], a role of SLC4A11 in Na+ and OH- home-
ostasis in the inner ear cannot be excluded. Comparative
SAGE analysis of gene expression profiles showed that
SLC4A11 is downregulated in Fuchs endothelial dystro-
phy [39]. In situ hybridization showed expression of
SLC4A11 in the mouse cornea at embryonic day 18, which
corresponds to human gestational month 5, the time at
which CHED pathology is believed to develop in humans
[4]. SLC4A11 is expressed in human corneal endothelium
as shown by reverse transcriptase polymerase chain reac-
tion (RT-PCR) [4].
Diagnostic methods
The diagnosis of CHED is based upon clinical criteria and
detailed ophthalmological assessment. All cases of auto-
somal recessive CHED (CHED2) and all cases of Har-
boyan syndrome reported so far have shown mutations
of, or have been consistent with linkage to SLC4A11, with
no evidence of genetic heterogeneity. A molecular confir-
mation of the clinical diagnosis is hence feasible.Page 5 of 8
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Harboyan as well as CHED2 patients present with bilat-
eral clouding of the entire cornea appearing within the
first years of life. Central corneal thickness is increased.
Slit lamp examination shows diffuse opacification with
epithelial and stromal edema (Figure 1B). Visual acuity is
usually severely affected and nystagmus may be present.
The endothelial barrier function can be assessed by
fluoro-photometrical method. Endothelial dystrophy can
be confirmed by the histopathologic findings of the
explanted cornea that show severely degenerated corneal
endothelial cells and abnormal thickening of Descemet's
membrane [18].
Audiometry
Tonal audiometry in patients with Harboyan syndrome
shows sensorineural hearing loss. Hearing loss is postlin-
gual, slowly progressive, with a variable age of onset, rang-
ing from 4 to 19 years in the patients studied to date, and
a variable degree of hearing loss, -30 dB to -60 dB, in one
study of six Harboyan families with various ethnic back-
grounds [20].
Differential diagnosis
The differential diagnosis between Harboyan syndrome
and CHED2 relies on the audiometry examination data,
showing hearing loss in Harboyan syndrome; otherwise,
both conditions share the same ocular abnormalities.
Harboyan syndrome and CHED2 differ from CHED1. In
CHED1, opacification is not present at birth and is usually
seen after the first or second year of life. In contrast to Har-
boyan syndrome and CHED2, accompanying signs such
as photophobia and epiphora are common presentation
of CHED1 (these signs taper with the progression of the
corneal clouding), but nystagmus is rarely observed.
A variety of genetic, metabolic, developmental, acquired,
and cryptogenic causes can result in congenital clouding
of the cornea. Congenital corneal opacities present in
approximately 3/100,000 newborns [40]. In a study by
Rezende et al [41], among 47 cases of congenital corneal
abnormalities, the first cause was Peters anomaly (40%),
followed by sclerocornea (18%), dermoid (15%), con-
genital glaucoma (7%), microphthalmia (4%), birth
trauma, and metabolic disease (3%). Seven cases (9%)
were classified as idiopathic. Ten patients had systemic
abnormalities associated with their ocular condition.
Peters anomaly is not an isolated anterior segment abnor-
mality. Rather, it occurs as a variable, phenotypically het-
erogeneous condition associated with several underlying
ocular and systemic defects. Central, paracentral, or com-
plete corneal opacity is always present in patients with
Peters anomaly. Blood vessels are typically not found
within the opaque portion of the cornea. This feature is
helpful to distinguish Peters anomaly from other causes of
congenital corneal opacity.
Sclerocornea is an uncommon developmental abnormal-
ity of the anterior segment due to mesenchymal dysgene-
sis. It is usually seen as an isolated ocular abnormality
involving both eyes, although it can occur unilaterally.
This condition typically occurs sporadically but may also
have a familial or autosomal dominant inheritance pat-
tern. On clinical evaluation, patients with partial sclero-
cornea have a peripheral, white, vascularized, 1- to 2-mm
corneal rim that blends with the sclera, obliterating the
limbus. The central cornea is generally normal. In total
sclerocornea, the entire cornea is involved, but the center
of the cornea is clearer than the periphery. This finding
distinguishes it from Peters anomaly, in which the center
is most opaque. The opacification affects the full thickness
of the stroma and hampers visualization of the posterior
corneal surface and of the intraocular structures (Figure
1B). Histopathology reveals disorganized collagenous tis-
sue containing fibrils that are larger than normal. Other
findings may be present which include a shallow anterior
chamber, abnormalities of the iris and the lens, and
microphthalmos. Systemic abnormalities, such as limb
deformities and craniofacial and genitourinary defects,
can also accompany this finding.
Limbal dermoids are benign congenital tumors that con-
tain choristomatous tissue (tissue not normally found at
that site). They most frequently appear at the inferior tem-
poral quadrant of the corneal limbus. However, they are
occasionally present entirely within the cornea or con-
fined to the conjunctiva. Inheritance is usually sporadic,
although autosomal recessive or sex-linked pedigrees
exist. They can be associated with corneal clouding.
Although most limbal dermoids are isolated findings,
approximately 30% are associated with Goldenhar syn-
drome, especially when they are bilateral.
Congenital glaucoma is an important cause of congenital
corneal clouding. CHED itself may cause glaucoma, and a
clear association between congenital glaucoma and con-
genital hereditary endothelial dystrophy has been
described. CHED should hence be suspected where per-
sistent and total corneal opacification fails to resolve after
normalization of intraocular pressure [42,43].
Genetic counseling
A genetic counseling is recommended in all cases of
CHED. The recurrence risk is 25% in siblings of both
CHED2 and Harboyan syndrome, with no symptoms
reported in heterozygous carriers. Care must be taken to
differentiate the autosomal recessive types of CHED
(CHED2 and Harboyan syndrome) from the autosomalPage 6 of 8
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tory, careful examination of relatives, SLC4A11 gene anal-
ysis, and clinical presentation, should allow to distinguish
the usually less severe CHED1, where deafness has not
been reported [17].
Management
Topical hyperosmolar solutions (hyertonic sodium chlo-
ride) produce temporary corneal dehydration and may be
beneficial in some patients.
Corneal transplantation (penetrating keratoplasty) is the
definitive treatment. It is recommended to avoid amblyo-
pia and to restore vision. Penetrating keratoplasty carries
a relatively good surgical prognosis and can produce a
substantial visual gain even when carried out late in life.
Postoperatively, patients should expect only gradual
recovery of vision. Following surgery, the best vision may
not be obtained after six to twelve months, or more.
Careful audiometry is recommended in all cases of
CHED2. Audiometric monitoring of hearing is advisable
because of non-congenital, progressive onset of hearing
loss in Harboyan syndrome, with some cases requiring
hearing aids.
Prognosis
All patients with Harboyan syndrome described to date
are in good general health, with no other systemic features
that reduce life expectancy. Corneal transplantation car-
ries a relatively good surgical prognosis and can produce
a substantial visual gain even when carried out late in life.
The disease has not been reported to recur after corneal
transplantation. In the absence of longitudinal data, the
hearing prognosis is presently unclear in the very young,
sporadic CHED patients.
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